Healthcare Industry News: Tryton Medical
News Release - February 18, 2010
Tryton Stent Implanted in First Cases in Portugal and AustriaCompany Celebrates 750th Implant
DURHAM, N.C.--(HSMN NewsFeed)--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the Tryton® stent has been implanted for the first time in Portugal and Austria.
Francisco Pereira Machado, M.D., of Hospital da Luz in Lisbon performed the first implant in Portugal.
“The Tryton Side Branch Stent is a simple approach to secure and dilate the side branch with optimal scaffolding of its ostium. Its use makes the placement and deployment of the main vessel stent easy,” said Dr. Machado. “When there is involvement of both the main vessel and the side branch, and when, for any reason, you choose to go for two stents, think of dedicated stents. Keep it simple.”
Olev Luha, M.D., Ph.D., from the LKH University Hospital in Graz was the first to use the Tryton Side Branch Stent in Austria and has implanted four Tryton stents during four different procedures.
"I am pleased to have had the opportunity to start using the Tryton Side Branch Stent. The Tryton is easy to use and allows for a predictable treatment of bifurcation lesions, which are some of the most complex lesions that we get to treat. Going forward, I will use the Tryton Side Branch Stent in my daily practice," said Dr. Luha.
“The rapid adoption of the Tryton Side Branch Stent is extremely gratifying. The system has now been implanted in more than 750 European patients,” said J. Greg Davis, president and CEO of Tryton Medical. “We are very pleased that the Tryton® stent is now available in Portugal and Austria, giving physicians in those countries a dedicated strategy for these difficult-to-treat areas of disease, which are a frequent occurrence – approximately one in every four cases.”
About the Tryton Side Branch Stent System
The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. These areas of the vascular system are a common location for plaque and are particularly challenging to treat with currently available stent systems. Approximately twenty-two percent of patients treated for coronary artery disease have diseased bifurcated lesions.
Tryton’s highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
The Tryton Side Branch Stent System demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery. The stent system has received CE Mark approval in Europe and is not approved in the United States.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company's Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. The privately held company is backed by Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.
Source: Tryton Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.